What does this article add?
KIM-1/TIM-1 acts as an important gateway to the entry of the virus into the cell and its increased level of severely ill patients seems to confirm this. Treatments for this gateway can play an important role in treatment in COVID-19. In addition, the falling level of suPAR, which plays a role in body defense and fibrinolisis, with the weight of the disease may be the cause of parenchymal fibrosis development in patients, increased predisposition to thromboembolic events and increased virulence. This issue seems to need to be confirmed through more extensive research.